However, Belimumab exhibits low efficacy for SLE treatment, we reasoned that it cannot totally blocks noncanonical NF-κB activation, since non-neutralized CD40L and TACI are also two major inducers for noncanonical pathway. The gene discussed is TNFRSF13B; the disease is systemic lupus erythematosus.